Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on May 29, 2026 by admin
<![CDATA[Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.]]>
CategoriesUncategorized TagsBipolar, Clinical trial, News Approved, Schizophrenia spectrum

Post navigation

Previous PostPrevious Co-Designing a Text Messaging Intervention for Youth Transitioning From Child to Adult Mental Health Services: Participatory Design Jam Study
Next PostNext AI-Powered Pan-Cancer Map Reveals Tertiary Lymphoid Structures
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.